Reading CLNN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CLNN free→Reading CLNN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CLNN free→NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality cannot be assessed as the company was unprofitable over the past year, but it has a capital-friendly stance. The sector backdrop is a headwind, and compared with sector peers, its performance is below typical. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $5.77. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Consumer Staples names rated weak grew net income 56% of the time over the next year (vs 58% for the rest of the cohort, n=1144).
Over the trailing year it converted 0.54x of net income into operating cash flow.
Not enough signal yet.
15 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Consumer Staples names rated volatile grew net income 42% of the time over the next year (vs 51% for the rest of the cohort, n=368).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.33 → $-0.26 (+20.0% / 30d). 0 raised, 0 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
via XLP
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Not enough price history for this read.
How much price usually moves either way.
Not enough price history for this read.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $920.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Management fell by 8.5 points (from 29.9 to 21.4).
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth speeds up, it could signal a positive shift in business. This would help counter the current weak performance.
Confirms:Revenue growth is speeding up again. It is now over 4% compared to last year.
Disproves:Revenue growth continues to slow or stays below 4% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CLNN yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. First Amendment to August 2025 Senior Secured Convertible Promissory Notes On May 18, 2026, Clene Inc. (the “Company”) entered into an amendment (the “Amendment”) to the senior secured convertible promissory notes (the “Notes”) with AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way. The Notes were issued on August 13, 2025. Pursuant to the Amendment, (i) the maturity date was extended to the earlier of (A) August 13, 2027 or (…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
A side-by-side read on sector standing, valuation, and risk versus Packaged Foods & Meats.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CLNN Clene Inc | Below typical Show detailsSector percentile: 12 of 100 | — | low |
MDLZ Mondelez International | Typical Show detailsSector percentile: 44 of 100 | expensive | moderate |
HSY Hershey Company (The) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
KHC Kraft Heinz | Above typical Show detailsSector percentile: 90 of 100 | fair | moderate |
TSN Tyson Foods | Above typical Show detailsSector percentile: 76 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Clene plans to submit a New Drug Application for CNM-Au8 under the accelerated approval pathway in the third quarter of 2026.
Stated in 2 of last 2 quarters. Clene plans to submit an NDA for CNM-Au8 in Q3 2026, but there is no financial impact yet as the submission is pending. The recurring focus on this regulatory milestone indicates its strategic importance, but substantive delivery is pending.
“Clene expects to submit an NDA for CNM-Au8 to the FDA in the third quarter of 2026.”
“Clene plans to submit an NDA for CNM-Au8 under the accelerated approval pathway in Q3 2026.”
Clene aims to extend its operating runway into the fourth quarter of 2026 with current resources.
Stated in 2 of last 2 quarters. Clene aims to extend its operating runway into Q4 2026. Despite a net loss of $8.1M in 2026-Q1, management maintains this guidance. The trajectory shows persistent statement, limited substantive delivery so far.
“Clene expects that its resources as of March 31, 2026, will provide operating runway into the fourth quarter of 2026.”
Clene is focused on managing cash flow and operating expenses to sustain operations.
Stated in 3 of last 3 quarters. Net loss decreased from $9.2M in 2025-Q4 to $8.1M in 2026-Q1, indicating some progress in managing expenses. However, cash flow remains negative, showing limited progress in achieving sustainable operations.
Results of Operations and Financial Condition. On May 14, 2026, Clene Inc. (the “Company”) issued a press release announcing its first quarter 2026 financial results and recent operating highlights for its quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 1…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended 2020 Stock Plan On May 21, 2026, the stockholders of the Company voted at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) to approve the Clene Inc. Amended 2020 Stock Plan (the “Plan”) to increase the number of shares of common stock, par value $0.0001 per share (“Common Stock”) reserved for issuance thereunder by 1…
Entry into a Material Definitive Agreement. Second Amendment to December 2024 Senior Secured Convertible Promissory Notes On May 11, 2026, Clene Inc. (the “Company”) entered into the second amendment (the “Second Amendment”) to the amended and restated senior secured convertible promissory notes (the “Amended Notes”) with Kensington Clene 2024, LLC (“Kensington”), 4Life Research, LLC (“4Life”) and La Scala Investments, LLC (“La Scala,” and collectively with Kensington and 4Life, the “Holders”…
Entry into a Material Definitive Agreement. On May 5, 2026, Clene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), at an offering price of $7.00 per share. Canaccord Genuity LLC is acting as the sole bookrunner in the offering, and Maxim Group LLC…
“Sufficient cash to fund operations into the fourth quarter of 2026.”
“Clene reported a net loss of $8.1 million for the first quarter of 2026.”
“Clene reported a net loss of $9.2 million for the fourth quarter of 2025.”
“Clene reported a net loss of $8.8 million for the third quarter of 2025.”